These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10382869)

  • 21. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group.
    Schmitz FJ; Verhoef J; Fluit AC
    Int J Antimicrob Agents; 1999 Aug; 12(4):311-7. PubMed ID: 10493607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates].
    Ishii Y; Ohno A; Yamaguchi K
    Jpn J Antibiot; 1994 Jan; 47(1):22-8. PubMed ID: 8114270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F; Cantón R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
    Jones RN
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):213-20. PubMed ID: 12493166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ; Jin YF
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T; Thomson CJ; Amyes SG
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.